Overview of INOmax

Quick Facts

Property	Description
Active Ingredient	Nitric Oxide (NO)
Form	Inhalation Gas
Pharmacological Class	Selective Pulmonary Vasodilator
General Purpose	To improve blood flow within the lungs
Origin	Synthetic (Manufactured Medical Gas)

Defining INOmax: Identity and Pharmacological Type

INOmax is the specific trade name for the prescription medicinal product, Nitric Oxide for inhalation. The active substance, Nitric Oxide (NO), is formally classified as a Selective Pulmonary Vasodilator, positioning it within the category of pharmaceutical agents used to promote the relaxation and widening of specific blood vessels. The product is a single-component drug and is manufactured as a synthetic, compressed medical gas, a characteristic differentiating it from systemic liquid or solid therapies.

Composition, Form, and Delivery Method

The unique dosage form of INOmax is a medical gas for inhalation, supplied in specialized pressurized cylinders. The chemical basis is the active Nitric Oxide molecule, which is diluted with an inert vehicle, nitrogen gas, to ensure stability and precise therapeutic delivery. The exclusive route of administration is inhalation, meaning the gas must be delivered directly into the patient's airways via specialized, calibrated equipment. The product is intended solely for this controlled pulmonary route.

General Purpose: How a Selective Vasodilator Helps

The essential purpose of this selective pulmonary vasodilator is to assist in the balancing of blood flow and air distribution within the lungs, thereby improving the overall efficiency of gas exchange. By selectively reducing resistance in the pulmonary blood vessels, the drug helps to redistribute blood flow toward the lung areas that are receiving adequate air. This targeted action supports the body's capacity to enhance oxygen uptake, a benefit of its localized pulmonary effect.

What side effects are possible with INOmax?

The regulatory safety profile for INOmax (Nitric Oxide for inhalation) details adverse reactions across several physiological systems, classified by frequency in official documents.

Frequency-Classified Adverse Reactions

The most frequent events in neonates include those classified as Very Common (ge 1 in 10 patients), which span Blood and Lymphatic System Disorders and Metabolism and Nutrition Disorders. These documented reactions include Thrombocytopenia (low platelet count), Hypokalemia (low serum potassium), Atelectasis (collapsed lung), and Hyperbilirubinaemia (elevated bilirubin). Hypotension (low blood pressure) is classified as a common or most common effect across clinical trials. The serious reaction Methemoglobinemia is classified as Uncommon, typically reaching its maximum level approximately eight hours after treatment initiation.

Serious Adverse Reactions and Safety Constraints

A major safety concern noted in the official labeling is the risk of Rebound Pulmonary Hypertension Syndrome, which is explicitly associated with the abrupt cessation of therapy. The label also documents the risk of Airway Injury due to the potential formation of nitrogen dioxide ( NO2) when the gas interacts with oxygen.

Regarding Population-Specific Safety, the medicine is contraindicated for use in neonates who are known to be dependent on right-to-left shunting of blood to maintain circulation. A safety restriction also applies to co-administration; using INOmax with other nitric oxide donor agents may increase the risk of developing Methemoglobinemia.

This official safety structure emphasizes critical, time-dependent events and established physiological constraints that define the acknowledged risk profile documented by government health authorities.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for INOmax (Nitric Oxide for inhalation) overdose is defined by two primary, dose-dependent toxicological concerns documented in government sources.

Documented Overdose Manifestations

Overexposure is primarily documented by Methemoglobinemia, where high methemoglobin levels compromise the blood's capacity to transport oxygen, leading to hypoxemia. Clinical signs of reduced oxygen delivery, such as a bluish appearance of the lips, palms, or fingernails, are specifically noted. The second key manifestation is the excessive formation of Nitrogen Dioxide ( NO2) gas, which is associated with the risk of acute lung injury and damage to the airways.

Emergency Response and Actions

Regulatory documents mandate that any patient showing signs of overdose, including clinical symptoms or laboratory confirmation of Methemoglobinemia, must seek immediate medical attention. The immediate procedural action is the prompt reduction or complete discontinuation of the inhaled nitric oxide dose. To treat Methemoglobinemia, the administration of intravenous methylene blue or Vitamin C (ascorbic acid) is documented. Patients with pre-existing left ventricular dysfunction are noted as a population specifically at increased risk of serious adverse events, including pulmonary edema and cardiac arrest, following exposure. Continuous monitoring of Methemoglobin and NO2 levels is required to detect early signs of overexposure.

Therapeutic Uses of INOmax

What INOmax Treats: Main Uses and Benefits

The therapeutic applications of INOmax are commonly used in situations involving certain distressing symptoms related to severe pulmonary and circulatory distress. The medication is considered relevant in clinical settings that involve acute or unstable symptom patterns where short-term symptomatic assistance is needed.

The primary therapeutic domains are focused on managing acute conditions such as conditions marked by heightened symptoms of severe oxygen deprivation in newborns and addressing pulmonary high pressure associated with cardiac procedures in patients of all ages. The supportive use is relevant for easing the pronounced symptoms of localized high blood pressure and low oxygen levels in the blood.

“The supportive benefit is relevant for easing the excessive pressure and contributes to managing blood oxygenation.”

This supportive relief is often used during phases when symptoms become more noticeable, helping to manage the overall burden of symptoms associated with severe circulatory strain and breathing difficulties.

Quick Fact: Relief for Pulmonary and Circulatory Strain

Feature	Therapeutic Focus
Symptom Cluster	High blood pressure in the lungs, low blood oxygen.
Primary Patient Groups	Term and near-term newborns and patients recovering from heart surgery.
Benefit	Contributes to supportive relief for blood oxygenation and helps manage circulatory stability.

Regulatory References

European Medicines Agency (EMA) therapeutic overview

Eligibility and Restrictions for Use

Who Can and Cannot Use INOmax?

Eligibility for INOmax (nitric oxide for inhalation) is strictly defined by regulatory authorities and is highly specific to the patient's age and clinical status.

Approved and Restricted Populations

Population	Eligibility Status
Term and Near-Term Neonates	Allowed ( ge 34 weeks gestation) for hypoxic respiratory failure.
Preterm Neonates	Not recommended or use not established (less than 34 weeks gestation).
Adults	Not indicated for general use (US label); permitted for pulmonary hypertension during heart surgery (EU label).

Absolute Contraindications and Limitations

INOmax must not be used in any neonate known to be dependent on right-to-left shunting of blood, which is specified in official labeling as an absolute contraindication. Use is also prohibited if the patient has a known hypersensitivity to nitric oxide. Special caution and close monitoring are required if the patient has pre-existing left ventricular dysfunction due to the risk of serious complications. As the medicine is not intended for adults, regulatory guidance states that passive exposure during pregnancy and lactation should be avoided.

What should I know about interactions with other medicines?

Official Interaction Profile

The official regulatory documentation for Nitric Oxide (INOmax) gas for inhalation details a highly specific pharmacodynamic interaction with a limited class of other medicinal products. The profile is primarily characterized by an additive effect with agents that also act as nitric oxide donors, which can lead to increased concentrations of methemoglobin in the blood.

Interaction Type	Agents Documented in Regulatory Labels
Nitric Oxide Donor Agents	Prilocaine, Sodium Nitroprusside, Nitroglycerin

Co-administration of INOmax with these Nitric Oxide Donor Agents—especially when they are given as oral, topical, or parenteral formulations—can increase the risk of developing methemoglobinemia. This outcome is the only formal, clinically significant drug-drug interaction detailed in the prescribing information.

Absence of Documented Interactions

The regulatory profile states that no formal studies have been performed to evaluate the possibility of complex pharmacokinetic interactions, such as those involving CYP-mediated enzyme activity or drug transporters. Consequently, the official labeling does not document any interactions with food, alcohol, herbal products, or supplements. Furthermore, there are no mandatory timing rules requiring the separation of INOmax administration from other agents. The drug's use is not associated with any specific drug-drug combinations classified as contraindicated.

Mechanism of Action

Activation of the Soluble Guanylate Cyclase (sGC) Pathway

The drug's action initiates at the molecular level with the active ingredient, Nitric Oxide (NO), functioning as an agonist by binding to and activating the enzyme soluble Guanylate Cyclase (sGC) found in the smooth muscle cells of the pulmonary vasculature. This binding rapidly triggers a signaling cascade, converting Guanosine Triphosphate (GTP) into the cyclic Guanosine Monophosphate (cGMP) second messenger. This mechanism leads directly to the relaxation of the smooth muscle by lowering the internal cellular concentration of calcium ions ( Ca^2+).

Selective Pulmonary Vasodilation and V/ Q Modulation

The delivery of Nitric Oxide as an inhaled gas confines its effective concentration to the blood vessels immediately surrounding the ventilated lung segments. This localized relaxation of pulmonary arterioles (selective vasodilation) results in the redistribution of pulmonary blood flow toward ventilated lung areas, which aligns with Ventilation-Perfusion ( V/ Q) principles. The route-dependent selectivity confines the vascular effect to the pulmonary circulation.

Rapid Inactivation by Hemoglobin

The functional selectivity of the mechanism is maintained by the immediate and high-affinity scavenging of Nitric Oxide by hemoglobin within the red blood cells upon entering the bloodstream. This rapid chemical inactivation converts the active molecule into inert compounds, such as methemoglobin and nitrates, which maintains the short duration and localized nature of the drug's physiological effect.

Dosage and Administration Information

The administration of INOmax (nitric oxide) is highly procedural and is restricted to specialized critical care settings. The medicinal gas is delivered continuously via the inhalation route and must be integrated directly into a patient's breathing circuit using a specialized, calibrated Nitric Oxide Delivery System (NODS).

Official Dosing and Duration

Patient Population	Starting Dose / Maximum Concentration
Neonates (≥ 34 weeks)	20 ppm (parts per million). Concentrations above this dose are not recommended.
Adults	Up to 40 ppm in cardiac-associated scenarios, then reduced.

For term and near-term neonates, the treatment may be maintained for up to 14 days or until the underlying condition has resolved. Treatment for adult cardiac patients is typically 24–48 hours, up to a maximum of seven days.

Administration Protocol

INOmax is administered continuously and abrupt discontinuation is strictly avoided. Treatment must be ceased through a mandatory gradual weaning protocol that reduces the dose over several steps, often down to a minimum of 1 ppm before final cessation.

Usage is limited to term and near-term neonates, as its application in premature infants (less than 34 weeks gestation) is not established. The delivery process requires the continuous, concurrent monitoring of the inspired nitric oxide concentration, the fraction of inspired oxygen (FiO2), and the concentration of nitrogen dioxide (NO2). The NO2 concentration must be maintained as low as possible, typically below 0.5 ppm.

Recent Clinical Evidence

INOmax: Recent Clinical Evidence

Clinical evidence for INOmax (inhaled nitric oxide) primarily focuses on its use in term and near-term neonates (gestational age 34 weeks) experiencing hypoxic respiratory failure (HRF) associated with persistent pulmonary hypertension of the newborn (PPHN). The goal of therapy in this population is to improve oxygenation.

Pivotal Clinical Trials

Two large, randomized, placebo-controlled trials—the Neonatal Inhaled Nitric Oxide Study (NINOS) and the Clinical Inhaled Nitric Oxide Research Group Initiative (CINRGI)—evaluated inhaled nitric oxide in neonates with HRF/PPHN.

Improvement in Oxygenation: In both trials, inhaled nitric oxide was associated with a significant improvement in oxygenation parameters, such as the partial pressure of arterial oxygen (PaO2) and the oxygenation index (OI), compared to the control groups.
Extracorporeal Membrane Oxygenation (ECMO) Use: Meta-analyses of these pivotal studies indicate that the use of inhaled nitric oxide may reduce the combined outcome of death or the need for ECMO (a form of life support) in this specific neonate population.

Other Evidence

Mortality: Individual trials and combined data analyses have generally not demonstrated a statistically significant difference in overall mortality between the groups receiving inhaled nitric oxide and those receiving control gas.
Long-Term Outcomes: Follow-up studies of the original trial participants, extending for at least six months, found no evidence suggesting that treatment with inhaled nitric oxide had an adverse effect on long-term neurological health, the need for rehospitalization, or the incidence of pulmonary disease.
Premature Infants: Clinical trials investigating inhaled nitric oxide use in premature infants (less than 34 weeks gestation), often for the prevention of chronic lung disease (bronchopulmonary dysplasia or BPD), have yielded inconsistent results, and the evidence base for efficacy in this population is considered limited.

Key Studies & References

Inhaled nitric oxide in the management of persistent pulmonary hypertension of the newborn: a meta-analysis (DARE)

Frequently Asked Questions (FAQ)

Common questions about INOmax (FAQ)

Q: Is INOmax the same thing as oxygen therapy?

According to regulatory documents, INOmax is classified as a selective pulmonary vasodilator, meaning it specifically works to relax blood vessels in the lungs to redistribute blood flow. This is a targeted pharmaceutical effect and is different from standard supplemental oxygen therapy. Official information confirms that INOmax is used in conjunction with a ventilator and other appropriate agents, not as a replacement for standard respiratory support.

Q: How quickly does INOmax start working after it is administered?

Official information indicates that the drug's effect on lung blood pressure and overall oxygenation is described as very rapid. Changes are typically seen within a short period, often within 5 to 20 minutes after the treatment begins. This rapid onset reflects the immediate local action of the inhaled gas within the pulmonary circulation.

Q: How long does the effect of INOmax last after treatment stops?

The active substance, nitric oxide, has an extremely short duration of action due to its rapid inactivation in the bloodstream. Upon entering the blood, it is quickly converted into inactive compounds by hemoglobin. Because of this, the physiological effect of the drug generally lasts only a few seconds once the flow of the gas is stopped.

Q: Are there any long-term effects of using INOmax?

Follow-up studies of the neonate population who participated in the original pivotal trials, extending for at least six months, did not find evidence suggesting an adverse effect on long-term neurological health, the need for rehospitalization, or the incidence of chronic lung disease in this studied population.

Q: Is a headache a common side effect of inhaling nitric oxide?

Headache is generally not listed among the most frequent adverse reactions experienced by the patient receiving treatment. However, official safety surveillance reports have noted headache in association with the accidental exposure of hospital staff to the nitric oxide gas.

Q: What kind of monitoring is needed while a patient is receiving INOmax?

Official documentation requires continuous and close monitoring during the entire period of administration. This includes measuring the concentration of the inhaled nitric oxide (NO) and other gases in the breathing circuit, such as oxygen ( FiO2) and nitrogen dioxide ( NO2). Periodic measurement of methemoglobin levels in the patient’s blood is also required.

Q: Can a patient be awake or mobile while receiving INOmax?

INOmax is required by official documents to be used only in specialized critical care settings because it must be administered through a dedicated delivery system integrated into the patient's breathing circuit. The patient's ability to be awake or mobile depends entirely on their underlying clinical status that requires this high level of care and ventilatory support.

Q: Is INOmax safe to use during pregnancy or while breastfeeding?

Limited data describes the use of inhaled nitric oxide in pregnant patients who have certain heart conditions to improve their oxygenation. For a breastfeeding patient, because the drug has an extremely short half-life, it is not anticipated to pass into the breast milk in significant amounts.

Q: Is there evidence that INOmax is studied for use in COVID-19 related lung problems?

The regulatory label specifies the approved uses for INOmax (primarily in newborns with hypoxic respiratory failure). Outside of this approved use, published medical literature indicates that inhaled nitric oxide has been investigated in research settings for patients with severe respiratory issues, including those associated with COVID-19.

Q: Why is INOmax not typically used outside of a hospital setting?

The administration of INOmax is highly complex and procedural. Official documentation requires that it be delivered using specialized, calibrated equipment, along with continuous gas monitoring, a backup power supply, and an independent reserve delivery system. These strict requirements restrict its use to controlled medical environments like critical care units.

Q: Can INOmax interact with pain medications or sedatives?

The official prescribing information for INOmax details a specific interaction with agents known as nitric oxide donors (e.g., prilocaine, nitroglycerin), as combining these can increase the risk of methemoglobinemia. Formal studies on the possibility of interactions with non-donor pain medications or common sedatives are not documented in the regulatory profile.

Q: Why is INOmax considered a highly specialized treatment?

Regulatory documents state that the treatment must be overseen by a physician with specific experience in intensive care. Furthermore, it can only be used in clinical units where staff have been trained to operate the specialized nitric-oxide delivery equipment. These requirements are put in place due to the complexity and critical nature of the therapy.

Q: How does INOmax affect heart function, if at all?

INOmax primarily acts locally on blood vessels in the lungs. However, regulatory warnings caution that patients with pre-existing left ventricular dysfunction may be at risk for related adverse events, such as worsening heart function or a decrease in the heart's pumping capacity.

Q: Is INOmax linked to any respiratory infections?

Respiratory infection is not listed among the most frequent adverse reactions in official documents. However, certain regulatory reports indicate that sepsis or infection has been reported as a less-common or post-marketing adverse event.

Q: Why is INOmax treatment generally time-limited?

Official product information states that the treatment is intended to be maintained only until the underlying acute medical condition (hypoxic respiratory failure) has resolved. The duration of treatment is therefore dictated by the patient’s clinical response and readiness to be gradually weaned off the gas.

Q: Can INOmax be used in conjunction with other types of pulmonary therapy?

Yes, official documentation indicates that INOmax is intended to be used in conjunction with ventilatory support. It has been administered safely in clinical settings with other common pulmonary treatments, such as surfactant therapy and high-frequency ventilation.

How should INOmax be stored and disposed of?

Mandatory Storage and Handling

INOmax is supplied as a compressed gas in aluminum cylinders, requiring specific handling and storage protocols mandated by regulatory authorities.

Storage Requirement	Official Condition
Temperature Limit	Cylinder temperature must not exceed 52 C (125 F).
Protection	Cylinders must be protected from shocks, falls, moisture, direct sunlight, and sources of heat or ignition.
Environment	Store and use only in a well-ventilated place and keep valves/fittings free from grease and oil.

Stability and Disposal

The delivery system must maintain stability, requiring a backup power supply and an independent reserve delivery system to be readily available. The cylinder pressure must be monitored via a pressure gauge to ensure continuous supply. The disposal of the cylinder and any unused contents must be in accordance with local, regional, national, and international regulations, with users directed to contact the supplier for specific instructions.

INOmax